Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 2, Pages 466
Publisher
MDPI AG
Online
2020-02-24
DOI
10.3390/cancers12020466
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible
- (2019) Qingbin Cui et al. Future Medicinal Chemistry
- Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study
- (2019) Ning Ji et al. Frontiers in Oncology
- Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells
- (2019) Zhuo-Xun Wu et al. BIOCHEMICAL PHARMACOLOGY
- Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells
- (2019) Qingbin Cui et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance
- (2019) Chao-Yun Cai et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance
- (2019) Jing-Quan Wang et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression
- (2019) Dan Liao et al. MOLECULES
- Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors
- (2018) Sebastian C. Köhler et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Mutidrug Resistance
- (2018) Bo Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structural basis of small-molecule inhibition of human multidrug transporter ABCG2
- (2018) Scott M. Jackson et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Structural basis of small-molecule inhibition of human multidrug transporter ABCG2
- (2018) Scott M. Jackson et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- ABC transporters as cancer drivers: Potential functions in cancer development
- (2018) Alice Domenichini et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance
- (2018) Ning Ji et al. BIOCHEMICAL PHARMACOLOGY
- Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells
- (2018) Ning Ji et al. CANCER LETTERS
- Modulating ROS to overcome multidrug resistance in cancer
- (2018) Qingbin Cui et al. DRUG RESISTANCE UPDATES
- Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells
- (2018) Wei Zhang et al. Frontiers in Pharmacology
- VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters
- (2018) Ning Ji et al. Frontiers in Pharmacology
- Structure of the human multidrug transporter ABCG2
- (2017) Nicholas M. I. Taylor et al. NATURE
- Localization of the placental BCRP/ ABCG2 transporter to lipid rafts: Role for cholesterol in mediating efflux activity
- (2017) John T. Szilagyi et al. PLACENTA
- Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies
- (2017) Jun Li et al. Oncotarget
- Venetoclax: First Global Approval
- (2016) Emma D. Deeks DRUGS
- Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines
- (2015) Lloyd T Lam et al. Cancer Cell International
- Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
- (2015) F. Cervantes-Gomez et al. CLINICAL CANCER RESEARCH
- The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade
- (2015) Rishil J. Kathawala et al. DRUG RESISTANCE UPDATES
- Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
- (2013) François Vaillant et al. CANCER CELL
- Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP)
- (2013) Danwen Yang et al. Future Oncology
- Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance
- (2011) Z. Shi et al. CANCER RESEARCH
- Dicer-Mediated Upregulation of BCRP Confers Tamoxifen Resistance in Human Breast Cancer Cells
- (2011) J. Selever et al. CLINICAL CANCER RESEARCH
- Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy
- (2009) M. H. Kang et al. CLINICAL CANCER RESEARCH
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading
- (2009) Oleg Trott et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin
- (2008) S. Kitamura et al. DRUG METABOLISM AND DISPOSITION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started